BioMed X Institute, Heidelberg, Germany.
Handb Exp Pharmacol. 2024;286:113-136. doi: 10.1007/164_2024_729.
In the evolving landscape of biomedical research, the convergence of molecular biology and translational medicine has ushered in a new era of pharmaceutical innovation. This paradigm shift, characterized by significant advances in targeted therapies and gene editing, emphasizes the critical role of integrating academic research - and academic researchers - within industry settings. Contemporary innovation models are moving beyond traditional, corporation-centered frameworks, adopting more open, collaborative approaches. Here, we discuss the challenges and solutions brought about by this new direction in pharma innovation and describe the BioMed X innovation model, a unique open innovation approach that has been growing continuously over the past ten years.
在不断发展的生物医学研究领域中，分子生物学和转化医学的融合带来了药物创新的新纪元。这一范式转变的特点是靶向治疗和基因编辑的显著进步，强调了将学术研究——以及学术研究人员——整合到工业环境中的关键作用。当代创新模式正在超越传统的、以公司为中心的框架，采用更加开放、协作的方法。在这里，我们讨论了药物创新这一新方向带来的挑战和解决方案，并描述了 Biomed X 创新模式，这是一种独特的开放式创新方法，在过去十年中一直在不断发展。
